The EASI-SWITCH trial: Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis.
Caroline Forde(Queen's University Belfast), Victoria Coyle(Queen's University Belfast), D. Storey(Western General Hospital), Richard Adams(Velindre Cancer Centre), Ian Chau(Royal Marsden NHS Foundation Trust), Ronan McMullan(Belfast Health and Social Care Trust), Elizabeth Ruth Plummer, Rosemary A. Barnes(Innsbruck Medical University), Margaret Grayson(The Northern Ireland Cancer Centre), Richard H. Wilson(Arizona State University), Ewan Brown(Western General Hospital), Anne Thomas(Leicester Royal Infirmary), Mike Clarke(University College Dublin), Ashley Agus(Belfast Health and Social Care Trust), Clíona McDowell
Cited by 1
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
|Clinical Microbiology and Infection|2018|1.5k